ARCA Hero Image
About ARCA

Our Focus

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs.

rNAPc2 is being developed as a potential treatment for patients hospitalized with COVID-19.  ARCA believes rNAPc2’s mechanism of action, along with safety data from prior human clinical trials in over 700 patients, provide a strong scientific rationale supporting evaluation of rNAPc2 as a potential therapeutic treatment for RNA virus associated diseases, including COVID-19.

Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation in patients with heart failure. ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted cardiovascular therapeutic.

About ARCA

Our Focus

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs.

rNAPc2 is being developed as a potential treatment for patients hospitalized with COVID-19.  ARCA believes rNAPc2’s mechanism of action, along with safety data from prior human clinical trials in over 700 patients, provide a strong scientific rationale supporting evaluation of rNAPc2 as a potential therapeutic treatment for RNA virus associated diseases, including COVID-19.

Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation in patients with heart failure. ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted cardiovascular therapeutic.

Management

Michael R. Bristow, M.D., Ph.D.

President & Chief Executive Officer

Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and served as Chairman and Chief Science and...[+more]

Thomas A. Keuer

Chief Operating Officer

Mr. Keuer was appointed to his current position as Chief Operating Officer in December 2014. He joined ARCA in October...[+more]

Jeff Dekker

Chief Financial Officer

Mr. Dekker joined ARCA in May 2021 as Chief Financial Officer.  Prior to joining ARCA, Mr. Dekker served in multiple...[+more]

Christopher D. Ozeroff

Senior Vice President & General Counsel

Mr. Ozeroff has been ARCA’s Senior Vice President and General Counsel since September 2004. From August 1999, Mr. Ozeroff was...[+more]

Debra Marshall M.D., FACC

Chief Medical Officer

Dr. Debra Marshall is the Chief Medical Officer at ARCA Biopharma. Dr. Marshall joined ARCA in 2016 and has spent...[+more]

Board of Directors

Robert E. Conway

Chairman

Mr. Conway, age 65, was appointed to the Board of Directors in September 2013, and has served as the Chairman...[+more]

Michael R. Bristow, M.D., Ph.D.

Chief Executive Officer

Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and served as Chairman and Chief Science and...[+more]

Linda Grais, M.D.

Director

Dr. Grais has served as a member of ARCA’s board of directors since May 2007. She is a former Partner...[+more]

Anders Hove M.D.

Director

Dr. Hove, age 53, has served as a member of the Board of Directors since February 2017. Dr. Hove is...[+more]

Dan Mitchell

Director

Dan Mitchell was appointed to the Company’s Board of Directors in February of 2014. Mr. Mitchell founded and is a...[+more]

Raymond L. Woosley, M.D., Ph.D.

Director

Dr. Woosley, age 70, was elected to the ARCA Board of Directors in July 2013. Dr. Woosley is currently President...[+more]